Taylor Lonjin, Dean Zhang, Praveen Prasanna
Excessive hemorrhage is a major contributor to morbidity and mortality in perioperative settings. Tranexamic acid (TXA), a synthetic antifibrinolytic agent, effectively reduces blood loss by preventing fibrin degradation. This review summarizes the clinical applications, efficacy, and safety considerations of TXA across various surgical specialties. A comprehensive review of studies across various surgical specialties confirms TXA's efficacy in minimizing the risk of hemorrhage and transfusion needs. While TXA is a valuable tool in hemostasis, proper patient selection and dosing are crucial to avoid risks, especially in those with thromboembolic conditions or renal impairment. Further research is needed to refine dosing protocols and expand its safe use across patient populations.